Is Embrybrugatinib tablets only used for the treatment of lung cancer?

Ambre (Brigatinib Tablets) is mainly used to treat specific types of lung cancer, especially anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). However, this does not mean that it is limited to the treatment of lung cancer. As a tyrosine kinase inhibitor, brigatinib works by inhibiting specific proteins in tumor cells to control the growth and spread of cancer cells.

Amberibrigtinib tablets have shown significant efficacy in the treatment ofALKpositiveNSCLC. Clinical trials have shown that the drug can extend patients' progression-free survival and improve objective response rates. Brigatinib provides an effective second-line treatment option for patients whose disease has progressed despite prior treatment with other ALK inhibitors.

Although brigatinib is mainly used to treat lung cancer, its mechanism of action suggests that it may also have certain effects on other tumors with similar biological characteristics. Currently, relevant studies are ongoing to explore the application of brigatinib in the treatment of other types of tumors. These studies provide more possibilities for the future application of brigatinib.

In terms of safety, brigatinib performed well in clinical trials. Although some adverse reactions may occur, most reactions are mild to moderate and can be relieved with appropriate symptomatic treatment. This makes brigatinib a relatively safe and well-tolerated treatment.

In summary, Ambrebrigatinib tablets are currently mainly used to treat ALKpositive NSCLC, but its potential application in the treatment of other types of tumors is also being studied and explored.

References:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208772s008lbl.pdf